CANOA Trial design: Patients undergoing percutaneous closure of an ASD with the Amplatzer Septal Occluder were randomized to aspirin 80 mg plus clopidogrel.

Slides:

Advertisements

Similar presentations

Migraine Intervention with STARFlex Technology (MIST) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Andrew.

Advertisements

Randomized, double-blind, multicenter, controlled trial.

Objective:To assess the effect of various clopidogrel and aspirin regimens on major CV events and ST in ACS patients undergoing PCI. Study:Multicenter,

A Review of – Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Ted Williams Pharm D Candidate Monday Lab.

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

Why Treat Patent Forman Ovale Clifford J Kavinsky, MD, PHD Professor of Medicine and pediatrics Associate Director, Center for Congenital and Structural.

(p for noninferiority = 0.01)

IRIS Trial design: Patients without diabetes with a history of stroke or TIA within 6 months, with objective evidence of insulin resistance (HOMA-IR value.

Study Trial design No. of patients Randomisation Outcomes assessed

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.

(CMR vs. guidelines, p < 0.001)

EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.

RE-CIRCUIT Trial design: Patients with atrial fibrillation undergoing catheter ablation were randomized to uninterrupted dabigatran 150 mg twice daily.

(p < for group 1 or 2 vs. group 3)

IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus.

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

AARDVARK Trial design: Patients with small abdominal aortic aneuryms (AAAs) were randomized in a 1:1:1 fashion to either perindopril 10 mg once daily,

LEVO-CTS Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min.

Angiography-guided PCI

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.

MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either.

MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those

Losartan vs. Atenolol in Marfan Syndrome

POSEIDON-DCM Trial design: Patients with nonischemic dilated cardiomyopathy were randomized to transendocardial injection of allogenic (n = 18) vs. autologous.

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

PRECISION Trial design: Patients with arthritis and increased cardiovascular risk were randomized to celecoxib 100 mg twice daily (n = 8,072) vs. ibuprofen.

Left atrial appendage closure: A new technique for clinical practice

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

ANTARCTIC Trial design: Patients with acute coronary syndrome undergoing stenting were randomized to tailored antiplatelet therapy (n = 435) versus conventional.

Atorvastatin for Reduction of Myocardial Damage During Angioplasty

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.

SMILE Trial design: NSTEMI patients were randomized to complete revascularization during the index procedure (i.e., 1-stage revascularization; n = 264)

FAMOUS-NSTEMI Trial design: Participants with NSTEMI were randomized to an FFR-guided strategy (n = 176) vs. a coronary angiography-guided strategy (n.

Modified Rankin score 0-2

Nat. Rev. Cardiol. doi: /nrcardio

ISAR-SAFE Trial design: Patients with DES PCI received 6 months of open-label DAPT with aspirin and clopidogrel. At 6 months, they were randomized in a.

ARNO TRIAL (Antithrombotic Regimens aNd Outcome)

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

(p < 0.05 for paclitaxel angioplasty vs. either control)

AMACING Trial design: Patients with chronic kidney disease undergoing intravascular iodinated contrast administration were randomized to prophylactic hydration.

(p < for noninferiority)

BRAVO-3 Trial design: Patients undergoing transfemoral TAVR were randomized in a 1:1 fashion to bivalirudin or UFH. They were followed for 30 days. Results.

IMPRESSION Trial design: Patients presenting with acute MI and undergoing an invasive approach, along with ticagrelor loading dose, were randomized to.

(p for noninferiority < 0.001)

(p = for noninferiority)

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

POPE-2 Trial design: Patients with moderate to large pericardial effusion after cardiac surgery were randomized to colchicine 2 mg loading dose, then 1.

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

Metoprolol for AR Trial design: Patients with chronic asymptomatic severe aortic regurgitation (AR) were randomized to metoprolol CR/XL 200 mg or matching.

Berger JS, et al. JAMA 2009;301:

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

STOP-CHAGAS Trial design: Asymptomatic patients with serological evidence of T. cruzi were randomized to posaconazole 400 mg BID, benznidazole 200 mg BID,

OPTIDUAL Trial design: Patients who received a drug-eluting stent and were event-free at 12 months were randomized to an additional 36 months of DAPT with.

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.

(p for noninferiority = 0.01)

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Section C: Clinical trial update: Oral antiplatelet therapy

Presentation transcript:

CANOA Trial design: Patients undergoing percutaneous closure of an ASD with the Amplatzer Septal Occluder were randomized to aspirin 80 mg plus clopidogrel 75 mg for 3 months (n = 84) vs. aspirin 80 mg plus placebo for 3 months (n = 87). Results (p = 0.035) Mean number of monthly migraine days per patient within 3 the months following ASD closure: 0.4 in the aspirin plus clopidogrel group vs. 1.4 in the aspirin plus placebo group (p = 0.035) New-onset migraine attacks: 9.5% in the aspirin plus clopidogrel group vs. 21.8% in the aspirin plus placebo group (p = 0.031) 1.4 0.4 Conclusions Among individuals undergoing percutaneous closure of an ASD, aspirin plus clopidogrel was effective at preventing new-onset migraine headache compared with aspirin alone This study confirms the occurrence of new-onset migraine headaches following ASD closure Aspirin plus clopidogrel Aspirin plus placebo Rodés-Cabau J, et al. JAMA 2015;314:2147-54